bpas comment on launch of first licensed medication for nausea and vomiting in pregnancy in the UK, Xonvea

Clare Murphy, Director of External Affairs at bpas, said:

“We welcome the news that finally, a license has been granted for a medication to treat nausea and vomiting in pregnancy. We know that many women are simply told to put up with debilitating symptoms on the basis that no medication is safe in pregnancy, when in fact the risks of not treating may be significantly higher. Our hope is that a licensed product will give doctors confidence to prescribe for women who need it. This is however no silver bullet, and it is important to note that if this medication does not work or symptoms deteriorate, a number of other safe medications are available even if they have not been specifically licensed for use in pregnant women. This medication is a first level of treatment for pregnancy sickness and will generally not be sufficient to treat the most severe form of the condition, Hyperemesis Gravidarum, the condition suffered by the Duchess of Cambridge. Bpas sees women whose sickness is so debilitating they are left with no choice but to terminate what is often a very much wanted pregnancy; with early treatment with medications including Xonvea, our hope would be that for at least some women, their symptoms and sickness will not escalate to the point that they need our services.”

ENDS

For media enquiries please call 0207 061 3377, 07788 725 185 or email press@bpas.org.

Notes to Editors:

About bpas

bpas is a charity which sees more than 70,000 women a year and provides reproductive healthcare services including pregnancy counselling, abortion care, miscarriage management and contraception, at clinics across the UK. It supports and advocates for reproductive choice. More information can be found at bpas.org.